Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)
Ian McGowan, Ian Frank, Susan H. Eshleman, Ken Ho, Robert A. Salata, Jorge Santana, Craig W. Hendrix, K. Rivet Amico, Albert Liu, Ying Qing Chen, Wairimu Chege, Alex R. Rinehart, Paul G. Richardson, Karin L. Klingman, Adriana Andrade, Raphael J. Landovitz, Mark A. Marzinke, Timothy Wilkin, Leslie M Cottle, Kenneth H. Mayer, Joanne D. Stekler, Cheryl Marcus, Alicia Young, Jason E. Farley, Manya Magnus, Roy M. Gulick, P. Andrew, James F. Rooney, Marybeth McCauley
Abstract
Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis.
Topics & Concepts
MaravirocTolerabilityHuman immunodeficiency virus (HIV)MedicineInternal medicineVirologyPharmacologyPsychologyAdverse effectHIV/AIDS Research and InterventionsMosquito-borne diseases and control